Potassium inwardly rectifying channel subfamily J member 16 (KCNJ16 (also commonly Kir5.1))

Potassium inwardly rectifying channel subfamily J member 16 (KCNJ16, Kir5.1) is a transmembrane protein forming an inward rectifier potassium channel. This channel allows potassium ions to move into cells more efficiently than out, especially present in epithelial cells of the kidney, pancreas, thyroid, and the brain[1][3][4][7]. Kir5.1 can form non-functional homomers or, more importantly, functional heteromers with Kir4.1 and Kir4.2 (encoded by KCNJ10 and KCNJ15), contributing to potassium recycling, maintaining the basolateral membrane potential, regulating acid-base and electrolyte balance—primarily in kidney distal convoluted tubules[5][4][7]. Variants in KCNJ16 cause disorders such as salt-wasting tubulopathies, metabolic acidosis, and deafness. Dysfunction of Kir5.1 has also implications in hypertension and roles in carcinogenesis. There are currently no approved drugs that directly target Kir5.1, but it is considered a valid therapeutic and diagnostic molecular target due to its physiological and pathophysiological importance[1][2][4][5][7].

Other names

KCNJ16Kir5.1BIR9Inward rectifier potassium channel 16Potassium channel, inwardly rectifying subfamily J member 16Potassium voltage-gated channel subfamily J member 16HKTD

Inhibition or modulation of potassium conductance: Drugs blocking or modulating Kir channels typically alter cellular excitability, fluid regulation, and electrolyte transport[1][2]. Indirect mechanisms: Potential actions might involve influencing systemic pH, sodium/potassium reabsorption, and others due to effects on renal function[2][4][5].